Fda grants rafael pharmaceuticals orphan drug designation for cpi-613® (devimistat) for treatment of soft tissue sarcoma

Company to launch clinical trial in clear cell sarcoma, a subtype of soft tissue sarcoma, in the coming months company to launch clinical trial in clear cell sarcoma, a subtype of soft tissue sarcoma, in the coming months
RFL Ratings Summary
RFL Quant Ranking